Inhibikase Therapeutics (NYSE:IKT – Get Free Report) had its target price cut by HC Wainwright from $27.00 to $23.00 in a report released on Tuesday, Benzinga reports. The firm currently has a “buy” rating on the stock. Inhibikase Therapeutics Trading Up 7.5 % Shares of Inhibikase Therapeutics stock opened at $1.86 on Tuesday. The firm’s […]